{
    "nct_id": "NCT03631199",
    "official_title": "A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)",
    "inclusion_criteria": "Key inclusion criteria:\n\n* Histologically confirmed locally advanced stage IIIB or stage IV NSCLC for treatment in the first-line setting\n* Known PD-L1 status determined by a Novartis designated central laboratory. A newly obtained tissue biopsy or an archival biopsy (block or slides) is required for PD-L1 determination (PD-L1 IHC 22C3 pharmDx assay), prior to study randomization. Note: For the safety run-in part, known PD-L1 status is not required.\n* Eastern Cooperative oncology group (ECOG) performance status of 0 or 1.\n* At least 1 measurable lesion by RECIST 1.1\n\nKey exclusion criteria:\n\n* Previous immunotherapy (e.g. anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways).\n* Prior treatment with canakinumab or drugs of a similar mechanism of action (IL-1β inhibitor).\n* Subjects with epidermal growth factor receptor (EGFR) sensitizing mutations (identified in exons 19, 20, or 21), and/or ALK rearrangement by locally approved laboratory testing.\n* Previously untreated or symptomatic central nervous system (CNS) metastases or lepto-meningeal disease.\n* Subject with suspected or proven immune-compromised state or infections.\n* Subject has prior to starting study drug: received live vaccination ≤3 months, had major surgery ≤4 weeks prior to starting study drug, has thoracic radiotherapy: lung fields ≤ 4 weeks, other anatomic sites ≤ 2 weeks, palliative radiotherapy for bone lesions ≤ 2 weeks.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}